Antiviral Drugs for Influenza in 2023-2024 - 1 AMA PRA Category 1 Credits
Tracking # 20-1191174
$9.00
There are no ratings for this course
Learn moreCourse overview
This course provides 1 AMA PRA Category 1 Credit, emphasizing the importance of antiviral treatment and vaccination to combat influenza during the 2023-2024 season. Influenza, commonly known as the flu, is a prevalent respiratory illness with the potential for severe complications. While it is often a self-limited condition, certain individuals face an elevated risk of complications such as pneumonia, respiratory failure, and even death. The 2023-2024 influenza season brings forth key recommendations for both treatment and prevention, including the use of specific antiviral drugs and the importance of vaccination.
Subject areas
This course counts toward the state boards and subject areas below.
Arizona Board of Podiatry Examiners
Podiatrist
Bahamas Medical Council
Medical Practitioner
Specialty Medical Practitioner
Florida Board of Medicine
Anesthesiologist Assistant
Area of Critical Need Medical Doctor
Medical Doctor
Medical Doctor Faculty Certificate
Medical Doctor Limited License
Medical Doctor Limited to Cleveland Clinic
Medical Doctor Limited to Mayo Clinic
Medical Doctor Public Health Certificate
Medical Doctor Public Psychiatry
Medical Doctor Visiting Faculty Certificate
Florida Board of Osteopathic Medicine
Osteopath Limited License
Osteopathic Area Critical Need
Osteopathic Physician
Florida Board of Podiatric Medicine
Podiatric Physician
Florida Council of Medical Physicists
Diagnostic Radiological Physicist
Medical Health Physicist
Medical Nuclear Radiological Physicist
Therapeutic Radiological Physicist
Florida Physician Assistants
Physician Assistant
Georgia Composite Medical Board - Physician Assistants
Physician Assistant
Georgia Composite Medical Board - Respiratory Care Professionals
Respiratory Care Professional
Louisiana State Board of Medical Examiners - Clinical Lab Personnel
Cytotechnologist
Generalist
Laboratory Assistant
Phlebotomist
Specialist
Technician
Louisiana State Board of Medical Examiners - Medical Psychologist
Medical Psychologist
Medical Psychologist Advanced Practice
Louisiana State Board of Medical Examiners - Physicians & Surgeons
Physician & Surgeon
Physician and Surgeon Compact License
Louisiana State Board of Medical Examiners - Podiatric Physicians
Podiatrist
Michigan Board of Medicine
Medical Doctor
Medical Doctor Compact License
Mississippi State Board of Medical Licensure
Doctor of Osteopathy
Medical Doctor
Physician Assistant
New Hampshire Board of Medicine
Physician
New Mexico Certified Nurse Midwives and Licensed Midwives
Certified Nurse Midwife
Licensed Midwife
New Mexico Medical Board
Doctor of Osteopathy
Medical Doctor
Oklahoma Board of Medical Licensure and Supervision - Medical Doctors
Medical Doctor
Oklahoma Board of Medical Licensure and Supervision - Physician Assistants
Physician Assistant
South Carolina Board of Medical Examiners
Doctor of Osteopathy
Medical Doctor
South Carolina Board of Podiatry Examiners
Podiatrist
State Medical Board of Ohio
Doctor of Medicine
Doctor of Osteopathic Medicine
Tennessee Board of Medical Examiners
Medical Doctor
Texas Medical Board - Physicians
Physician
Wisconsin Medical Examining Board
Physician
Disclosure statements
ACCME Activity ID 202583618
Learning Objectives
Upon completion of this activity, the participant will be able to:
- Discuss the 2023–2024 recommendations for antiviral treatment and prophylaxis of influenza.
- Compare the antiviral drugs available for treatment of influenza based on their efficacy, dosage and administration, and potential adverse effects.
- Review the influenza vaccines available in the US for the 2023-2024 season and discuss which vaccines are appropriate for specific patient populations.
- Discuss the risks and benefits associated with seasonal vaccination against influenza.
This CME activity was planned and produced in accordance with the ACCME Essentials and Policies through the joint providership of The Medical Letter and AchieveCE. The Medical Letter is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The Medical Letter ® designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™.
AchieveCE’s full accreditation list can be found on their accreditations page. It is the policy of AchieveCE not to accept any commercial support for any course(s). AchieveCE’s courses can be taken at-your-own-pace, online from any device and they report to CE Broker within 24 hours.
Take it Here
- Reports to CE broker immediately upon completion
- Can be completed fully online, at-your-own-pace
- Is accessible from any device, mobile, tablet, or desktop